Evidence map›Paper›PMID 33932114›Full record

Trial reportCancer medicine2021

Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.

Akira Yokomizo, Hirofumi Koga, Kazuto Ito, Yutaka Takezawa, Motokiyo Komiyama, Kazuo Nishimura, Junji Yonese, Katsuyoshi Hashine, Naoya Masumori, Gaku Arai and 25 more

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 2 countries.

Akira YokomizoDepartment of Urology, Graduate School of Medicine, Kyusyu University, Fukuoka, Japan.ORCID 0000-0002-5741-6280
Hirofumi KogaDepartment of Urology, Graduate School of Medicine, Kyusyu University, Fukuoka, Japan.
Kazuto ItoDepartment of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan.ORCID 0000-0002-3735-2769
Yutaka TakezawaDepartment of Urology, Isesaki Municipal Hospital, Isesaki, Japan.
Motokiyo KomiyamaDepartment of Urology, National Cancer Center Hospital, Tokyo, Japan.
Kazuo NishimuraDepartment of Urology, Osaka International Cancer Institute, Osaka, Japan.
Junji YoneseDepartment of Urology, Cancer Institute Hospital, Tokyo, Japan.
Katsuyoshi HashineDepartment of Urology, Shikoku Cancer Center, Matsuyama, Japan.
Naoya MasumoriDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Gaku AraiDepartment of Urology, Dokkyo University Koshigaya Hospital, Koshigaya, Japan.
Shiro SaitoDepartment of Urology, Tokyo Medical Center, Tokyo, Japan.
Mitsuru ShinoharaDepartment of Urology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Nobuaki ShimizuDepartment of Urology, Gunma Cancer Center Hospital, Ohta, Japan.
Atsushi YamauchiDepartment of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Takefumi SatohDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
Tatsuo TochigiDepartment of Urology, Miyagi Cancer Center, Natori, Japan.
Mikio KobayashiDepartment of Urology, Isesaki Municipal Hospital, Isesaki, Japan.
Hiroyuki FujimotoDepartment of Urology, National Cancer Center Hospital, Tokyo, Japan.
Ken-Ichi KakimotoDepartment of Urology, Osaka International Cancer Institute, Osaka, Japan.
Iwao FukuiDepartment of Urology, Cancer Institute Hospital, Tokyo, Japan.
Taiji TsukamotoSapporo Medical University School of Medicine, Sapporo, Japan.
Miwako NozakiDepartment of Radiation Oncology, Dokkyo University Koshigaya Hospital, Koshigaya, Japan.
Katsuyuki KarasawaDepartment of Radiation Oncology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Masaru HasumiDepartment of Urology, Gunma Cancer Center Hospital, Ohta, Japan.
Mikinobu OhtaniDepartment of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Hiromichi IshiyamaDepartment of Radiation and Radiation Oncology, Kitasato University, Sagamihara, Japan.
Masaaki KuwaharaSendai Jin-hinyokika, Sendai, Japan.
Masaoki HaradaKanagawa Cancer Center, Yokohama, Japan.
Yasuo OhashiUniversity of Tokyo, Tokyo, Japan.
Toshihiko KotakeKotake Clinic, Osaka, Japan.
Tadao KakizoePresident, Japan Cancer Society, Tokyo, Japan.
Kazuhiro SuzukiDepartment of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Seiji NaitoDepartment of Urology, Graduate School of Medicine, Kyusyu University, Fukuoka, Japan.
Hidetoshi YamanakaInstitute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan.
National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators
Kyushu University · JPDokkyo University · JPGunma Children's Medical Center · JPGunma University · JPIbaraki Prefectural Central Hospital · JPIsesaki Fukushima Hospital · JPKitasato University · JPOsaka International Cancer Institute · JPSapporo Medical University · JPThe Cancer Institute Hospital · JPTokyo Metropolitan Komagome Hospital · JPTokyo National Hospital · JPJapan Cancer Society · JPKanagawa Prefectural Hospital Organization · JPKurosawa Hospital · JPMiyagi Prefectural Hospital Organization · JPSendai Medical Center · JPShikoku Cancer Center · JPSt. Luke's Clinic · USThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe evaluated patient-reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca).

methodsA multicenter, randomized phase III trial enrolled 303 patients with locally advanced Pca. The patients were treated with 6 months (M) of ADT followed by 72 Gy of EBRT, and were randomly assigned to CADT or IADT after 14 M. The PROs were evaluated at sic points: baseline, 6 M, 8 M, 14 M, 20 M, and 38 M using FACT-P questionnaires and EPIC urinary, bowel, and sexual bother subscales.

resultsThe FACT-P total scores were significantly better (p < 0.05) in IADT versus CADT at 20 M (121.6 vs.115.4) and at 38 M (119.9 vs. 115.2). The physical well-being scores (PWB) were significantly better (p < 0.05) in IADT versus CADT at 38 M (25.4 vs. 24.0). The functional scores were significantly better in IADT than those in CADT at 14 M (20.2 vs18.7, p < 0.05) and at 20 M (21.0 vs.18.9, p < 0.05).

conclusionThe PRO was significantly favorable in IADT on FACT-P total score at 20 M and 38 M, PWB and functional scores at 38 M.

Indexed as

Aged, 80 and overAndrogen AntagonistsCombined Modality TherapyHumansMaleNeoadjuvant TherapyPatient Reported Outcome MeasuresProstatic NeoplasmsAndrogen Antagonistsexternal beam radiation therapyintermittent androgen deprivation therapyneoadjuvantprostate cancerQOL

Identifiers

PMID33932114
PMCPMC8124125
OpenAlexW3159422965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.